	US 12,350,381 B2
	Nanoparticles containing cellular membrane and uses thereof
Weiwei Gao, San Diego, CA (US); Huiqing Zhu, San Diego, CA (US); Jian Guan, San Diego, CA (US); and Yu-Wen Li, San Diego, CA (US)
Assigned to ARYTHA BIOSCIENCES, LLC, San Diego, CA (US); and CELLICS THERAPEUTICS INC., San Diego, CA (US)
Appl. No. 17/296,200
Filed by ARYTHA BIOSCIENCES, LLC, San Diego, CA (US); and CELLICS THERAPEUTICS INC., San Diego, CA (US)
PCT Filed Nov. 25, 2019, PCT No. PCT/US2019/063110 § 371(c)(1), (2) Date May 21, 2021, PCT Pub. No. WO2020/112694, PCT Pub. Date Jun. 4, 2020.
Claims priority of provisional application 62/771,561, filed on Nov. 26, 2018.
Prior Publication US 2022/0362162 A1, Nov. 17, 2022
Int. Cl. A61K 9/50 (2006.01); A61K 9/127 (2025.01)

CPC A61K 9/5068 (2013.01) [A61K 9/127 (2013.01); A61K 9/5015 (2013.01); A61K 9/5089 (2013.01)]

16 Claims

1. A nanoparticle comprising an interior compartment and an outer surface comprising a cellular membrane isolated from a cell, said interior compartment not providing a solid support to said cellular membrane in said outer surface, and wherein:

a) said interior compartment comprises a liquid that is isotonic to a human cellular or physiological liquid; and

b) said outer surface comprises a steroid at a level from 40% (w/w) to 45% (w/w) and a sphingolipid at a level from 40% (w/w) to 50% (w/w), and from 10% (w/w) to 20% (w/w) said cellular membrane isolated from said cell, and

wherein said nanoparticle is prepared by an in vitro process.